Risk Factors Linked to Infection with SARS-Cov2

Zagaouch D; Naama.S; Nader S; Berkchi M; Benaamour J; Bourkadi JE.1

1

Publication Date: 2021/06/11

Abstract: Infection with the SARS- CoV -2 ( Severe Acute Respiratory Syndrome ) is characterized by a wide spectrum of clinical syndromes ranging from disease asymptomatic, mild flu-like symptoms to severe pneumonia and acute respiratory distress syndrome Our goal is to study the risk factors in patients infected with COVID 19 ( Coronavirus disease 2019).  Methods : This is a retrospective descriptive study of 54 patients hospitalized in unit B- COVID-19 at the Ibn Sina University Hospital Center in Rabat from 15 October 2020 to 1 November 2020.  Results: Fifty-four cases of COVID-19 confirmed by PCR (Polymerase chain reaction) were hospitalized including 30 women (55,56%) and 24 men (44,44%), divided into 27 cases with a non-severe form and 27 cases with a moderate to severe form requiring oxygen therapy. The overall median age was 55,13 years. Fever (18,52%), dyspnea (38,89 %), cough (22,22%) and fatigue (11,11%) were the most common clinical manifestations, while diabetes (40,74%), arterial hypertension (27,78%) and obesity (14,81%) were the most common comorbidities . Chronic smokers (12.96%) patients with the bronchopulmonary disease chronic obstructive pulmonary disease (COPD, 1,54 %) and asthma (1,54%) were rare. Bilateral frosted glass or uneven opacity (66.71%) was the most common sign on the chest CT scan. Lymphopenia (37,04 %) and eosinopenia (29,36 %) were observed in our patients. Significantly higher values of D-dimer, C-reactive protein (CRP) and LDH were observed especially in patients with moderate to severe form.  Conclusion: Advanced age, diabetes and high blood pressure remain the most frequent risk factors for developing moderate to severe forms of viral infection with SARSCoV-2, hence the importance of taking in this category of patients. Lymphopenia, eosinopenia and inflammatory syndrome could be potential indicators of diagnosis and severity

Keywords: SARS- CoV-2, Comorbidities, Risk Actors

DOI: No DOI Available

PDF: https://ijirst.demo4.arinfotech.co/assets/upload/files/IJISRT21MAY706.pdf

REFERENCES

No References Available